Highlights From the 2021 SABCS Symposium

December 7-10, 2021; San Antonio, Texas
Download this summary slideset that includes key data from studies presented at the 2021 SABCS Symposium.
Format: Microsoft PowerPoint (.ppt)
File Size: 754 KB
Released: December 16, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Novartis Pharmaceuticals Corporation
Sanofi Genzyme
Seagen Inc.

Related Content

Dr Yara Abdou discusses BRCA mutation testing and adjuvant therapy with olaparib in BRCA-mutated, HER2-negative early breast cancer, from Clinical Care Options (CCO)

Yara Abdou, MD Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: May 17, 2022 Expired: May 16, 2023

Slideset from Dr Yara Abdou on adjuvant olaparib in BRCA1/2-mutated, HER2-negative early breast cancer, from Clinical Care Options (CCO)

Yara Abdou, MD Released: May 17, 2022

Dr. Yara Abdou discusses Ki-67 testing and adjuvant abemaciclib in HR+/HER2-, node-positive, high-risk early breast cancer, from Clinical Care Options (CCO)

Yara Abdou, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: May 12, 2022 Expired: May 11, 2023

Slideset from Dr. Yara Abdou on Ki-67 and adjuvant abemaciclib for HR+/HER2-, node-positive, high-risk EBC, from Clinical Care Options (CCO)

Yara Abdou, MD Released: May 12, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings